VT6 Panoramica delle azioni Voyager Therapeutics, Inc. è una società di biotecnologie che si concentra sul trattamento della terapia genica e delle malattie neurologiche. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Voyager Therapeutics, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Voyager Therapeutics Prezzi storici delle azioni Prezzo attuale dell'azione US$5.77 Massimo di 52 settimane US$9.90 Minimo di 52 settimane US$5.01 Beta 0.93 Variazione di 1 mese -4.07% Variazione a 3 mesi -9.70% Variazione di 1 anno -27.88% Variazione a 3 anni 135.13% Variazione a 5 anni -55.62% Variazione dall'IPO -68.59%
Notizie e aggiornamenti recenti
Voyager Therapeutics, Inc. Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease and Anticipates Filing an Investigational New Drug Application with the U.S. Food and Drug Administration and Clinical Trial Application with Health Canada for VY1706 in 2026 Nov 21
Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.59 loss in 3Q 2023) Nov 13
Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
Investor sentiment deteriorates as stock falls 22% Oct 24
Investor sentiment improves as stock rises 23% Oct 08
Investor sentiment deteriorates as stock falls 23% Aug 14 Vedi altri aggiornamenti
Voyager Therapeutics, Inc. Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease and Anticipates Filing an Investigational New Drug Application with the U.S. Food and Drug Administration and Clinical Trial Application with Health Canada for VY1706 in 2026 Nov 21
Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.59 loss in 3Q 2023) Nov 13
Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
Investor sentiment deteriorates as stock falls 22% Oct 24
Investor sentiment improves as stock rises 23% Oct 08
Investor sentiment deteriorates as stock falls 23% Aug 14
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.51 loss in 2Q 2023) Aug 07
Voyager Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 30
Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 2500 Growth Index Jul 03
Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024 Jun 15
Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease May 18
First quarter 2024 earnings released: US$0.20 loss per share (vs US$3.05 profit in 1Q 2023) May 14
Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER™?-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting May 09
Voyager Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024 May 08
Investor sentiment improves as stock rises 16% May 04
Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024 Apr 28
President recently sold €111k worth of stock Apr 05
Investor sentiment improves as stock rises 17% Apr 02
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024 Mar 15
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024 Mar 13
Full year 2023 earnings released: EPS: US$3.08 (vs US$1.21 loss in FY 2022) Feb 29
Investor sentiment improves as stock rises 27% Feb 29
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment Feb 28
President recently sold €90k worth of stock Feb 27
Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 22
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research Feb 20
New major risk - Shareholder dilution Jan 09
Voyager Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Jan 06 Voyager Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.
Investor sentiment improves as stock rises 26% Jan 02
Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program Dec 06
Third quarter 2023 earnings released: US$0.59 loss per share (vs US$0.46 profit in 3Q 2022) Nov 07
Voyager Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 31
Chief Financial Officer recently sold €91k worth of stock Oct 06
Second quarter 2023 earnings released: US$0.51 loss per share (vs US$0.50 loss in 2Q 2022) Aug 04
Voyager Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29
Investor sentiment deteriorates as stock falls 16% Jul 13
Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer Jul 11
Investor sentiment improves as stock rises 16% Jun 12
Investor sentiment improves as stock rises 19% May 18
Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee May 10
First quarter 2023 earnings released: EPS: US$3.05 (vs US$0.56 loss in 1Q 2022) May 10
President recently sold €54k worth of stock Apr 09
Chief Operating Officer recently sold €120k worth of stock Mar 22
Full year 2022 earnings released: US$1.21 loss per share (vs US$1.89 loss in FY 2021) Mar 09
Voyager Therapeutics, Inc. Appoints Grace E. Colón, Ph.D., to Its Board of Directors, Effective on January 1, 2023 Dec 15
Third quarter 2022 earnings released: EPS: US$0.46 (vs US$0.67 loss in 3Q 2021) Nov 09
Voyager Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Voyager Therapeutics, Inc Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families Oct 12 Voyager Therapeutics Appoints Peter Pfreundschuh as CFO, Effective September 19, 2022
Second quarter 2022 earnings released: US$0.50 loss per share (vs US$0.80 loss in 2Q 2021) Aug 06 Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models Aug 04
Voyager Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Aug 03
Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to Its Board of Directors Jul 29
Voyager Therapeutics, Inc. Announces Executive Changes Jun 09
Voyager Therapeutics, Inc. to Present New Preclinical Data on Family of AAV9-Derived Tracer Capsids Demonstrating Cross-Species Central Nervous System (CNS) Transduction May 20
Voyager Therapeutics, Inc. to Present Preclinical Data from Its Vectorized Anti-Her2 Antibody Program and A Novel Aav5-Derived Tracer™ Capsid At the 25Th American Society of Gene and Cell Therapy Annual Meeting May 18
First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.58 loss in 1Q 2021) May 06
Voyager Therapeutics, Inc., Annual General Meeting, Jun 06, 2022 Apr 22
Mark Levin and Steven Paul Requests Voyager Therapeutics Not to Nominate for Re-Election to the Board Apr 21
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 09
Voyager Therapeutics, Inc. Announces Executive Appointments Feb 04
Third quarter 2021 earnings released: US$0.67 loss per share (vs US$2.30 profit in 3Q 2020) Nov 03
Investor sentiment deteriorated over the past week Oct 27
Investor sentiment improved over the past week Oct 07
Investor sentiment improved over the past week Sep 06
Investor sentiment deteriorated over the past week Aug 17
Second quarter 2021 earnings released: US$0.80 loss per share (vs US$0.23 loss in 2Q 2020) Aug 10 Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 3000E Index
Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates May 12
First quarter 2021 earnings released: US$0.58 loss per share (vs US$0.66 loss in 1Q 2020) May 11
Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease Apr 27
Investor sentiment improved over the past week Apr 26
Full year 2020 earnings released: EPS US$0.99 (vs US$1.21 loss in FY 2019) Feb 28
Revenue misses expectations Feb 28
The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Feb 26
New 90-day low: €5.30 Feb 20
Voyager Therapeutics, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 19
Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Voyager Therapeutics, Inc Feb 17
Neurocrine Biosciences, Inc. Enters into Partial Termination of the Collaboration and License Agreement with Voyager Therapeutics, Inc Feb 03
Pomerantz Law Firm Announces the Filing of Class Action Against Voyager Therapeutics, Inc Jan 24
Wendy Dixon Decides to Resign from the Board and All Committees of Voyager Therapeutics, Inc Jan 16
Investor sentiment improved over the past week Jan 09
New 90-day low: €6.00 Dec 30
Investor sentiment deteriorated over the past week Dec 29
New 90-day low: €6.45 Dec 11
Market pulls back on stock over the past week Nov 16
Third quarter 2020 earnings released: EPS US$2.30 Nov 11
New 90-day low: €7.50 Nov 11 Rendimenti per gli azionisti VT6 DE Biotechs DE Mercato 7D 6.7% 2.5% -0.4% 1Y -27.9% -10.2% 7.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: VT6 ha avuto una performance inferiore rispetto al German Biotechs che ha registrato un rendimento -10.2 % nell'ultimo anno.
Rendimento vs Mercato: VT6 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 7.9 % nell'ultimo anno.
Volatilità dei prezzi Is VT6's price volatile compared to industry and market? VT6 volatility VT6 Average Weekly Movement 14.2% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Prezzo delle azioni stabile: Il prezzo delle azioni di VT6 è stato volatile negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 14% ) di VT6 è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.
Informazioni sull'azienda Voyager Therapeutics, Inc. è una società di biotecnologie che si concentra sul trattamento della terapia genica e delle malattie neurologiche. Il candidato clinico principale dell'azienda è VY-TAU01, un programma di anticorpi anti-tau per il trattamento della malattia di Alzheimer. La sua pipeline di prodotti comprende la terapia genica per il silenziamento della superossido dismutasi 1, in fase di sperimentazione preclinica per il trattamento della sclerosi laterale amiotrofica; la terapia genica per il silenziamento della tau, in fase di sperimentazione preclinica per il trattamento della malattia di alzheimer; e l'anticorpo anti-amiloide vettorizzato, una terapia genica mirata all'anti-amiloide per il trattamento della malattia di alzheimer, in fase di sperimentazione preclinica.
Mostra di più Voyager Therapeutics, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Voyager Therapeutics con la sua capitalizzazione di mercato? VT6 statistiche fondamentali Capitalizzazione di mercato €320.17m Guadagni(TTM ) €25.11m Ricavi(TTM ) €158.94m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) VT6 Conto economico (TTM ) Ricavi US$163.78m Costo del fatturato US$117.54m Profitto lordo US$46.24m Altre spese US$20.36m Guadagni US$25.88m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 0.47 Margine lordo 28.23% Margine di profitto netto 15.80% Rapporto debito/patrimonio netto 0%
Come si è comportato VT6 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/05 15:58 Prezzo dell'azione a fine giornata 2025/01/03 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Voyager Therapeutics, Inc. è coperta da 25 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Brian Skorney Baird Jack Allen Baird Aydin Huseynov Benchmark Company
Mostra 22 altri analisti 
